Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05662345 · ClinicalTrials.gov registry record
ACT-MBC: A Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer (MBC)
A clinical trial of Metastatic Breast Cancer, sponsored by Menarini Silicon Biosystems.
- Active
- Registry status
- 65
- Enrollment target
- 4
- Study locations
NCT05662345: Active study of Metastatic Breast Cancer, sponsored by Menarini Silicon Biosystems.
NCT05662345 is a study of Metastatic Breast Cancer that is active but no longer recruiting, run by Menarini Silicon Biosystems. The registered enrollment target is 65 participants, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (68% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05662345, a study of Metastatic Breast Cancer, is active but no longer recruiting, sponsored by Menarini Silicon Biosystems.
- ACTIVE NOT RECRUITING
- Registry status
- 65 participants
- Enrollment target
- 4
- Study locations
Study Summary
ACT-MBC prospectively assesses the impact of CTCs on treatment decisions, response assessment and prognosis in MBC patients.
Primary Outcome
Assessing proportion of providers that find CellSearch CTCs helpful in determining response to therapy in each unique patient (Questionnaire #2).
Conditions Studied
Interventions
- DIAGNOSTIC_TEST CellSearch Circulating Tumor Cells
Study Locations (4)
Minnesota
- Mayo Clinic Health System Albert Lea - Albert Lea
- Mayo Clinic Health System Mankato - Mankato
- Mayo Clinic - Rochester
Wisconsin
- MCHS Eau Claire - Eau Claire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2022-12-12 |
| Est. Completion | 2026-10 |
What the registry record for NCT05662345 still lists
NCT05662345 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which CellSearch Circulating Tumor Cells is the first listed.
NCT05662345 reports a single indexed study location in Minnesota, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT05662345 about?
NCT05662345 is a clinical study titled "ACT-MBC: A Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer (MBC)". ACT-MBC prospectively assesses the impact of CTCs on treatment decisions, response assessment and prognosis in MBC patients.
What is the current status of trial NCT05662345?
This trial is currently active not recruiting. The enrollment target is 65 participants. The study started on 2022-12-12. Estimated completion is 2026-10.
What conditions does trial NCT05662345 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer.
What interventions are being tested in trial NCT05662345?
The interventions under investigation include: CellSearch Circulating Tumor Cells (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05662345?
This trial is sponsored by Menarini Silicon Biosystems, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05662345 being conducted?
This trial has 4 study locations across Minnesota, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05662345's enrollment target sits among peer trials
65 74th of 139 higher than 65 of 139 other Metastatic Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
RECRUITING · Phase 1
-
Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
RECRUITING · Phase 2
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
RECRUITING · Phase 2
-
BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer
RECRUITING · NA
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI